FNY Investment Advisers LLC Acquires 56,342 Shares of Kenvue Inc. $KVUE

FNY Investment Advisers LLC lifted its stake in Kenvue Inc. (NYSE:KVUE) by 36.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 209,659 shares of the company’s stock after buying an additional 56,342 shares during the period. Kenvue makes up approximately 1.0% of FNY Investment Advisers LLC’s investment portfolio, making the stock its 17th biggest position. FNY Investment Advisers LLC’s holdings in Kenvue were worth $3,616,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. American Century Companies Inc. lifted its position in shares of Kenvue by 22.4% during the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares during the period. Dimensional Fund Advisors LP raised its stake in Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after purchasing an additional 2,747,952 shares in the last quarter. Van ECK Associates Corp raised its stake in Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after purchasing an additional 9,240,434 shares in the last quarter. Invesco Ltd. lifted its position in Kenvue by 11.0% during the second quarter. Invesco Ltd. now owns 17,818,771 shares of the company’s stock worth $372,947,000 after purchasing an additional 1,759,065 shares during the period. Finally, Amundi boosted its position in shares of Kenvue by 21.6% during the 3rd quarter. Amundi now owns 17,645,761 shares of the company’s stock worth $277,012,000 after acquiring an additional 3,135,871 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.2%

Shares of KVUE opened at $17.16 on Friday. The stock’s 50-day moving average price is $18.00 and its two-hundred day moving average price is $17.10. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a market capitalization of $32.90 billion, a PE ratio of 22.29, a PEG ratio of 3.95 and a beta of 0.61. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is presently 107.79%.

Wall Street Analyst Weigh In

Several brokerages have commented on KVUE. Citigroup boosted their price objective on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group lifted their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. UBS Group upped their price objective on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.58.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.